Diligence memo · auto-generated · as of July 2, 2026
Lycera Corp
Lycera Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Lycera Corp operates in Pharmaceuticals, based in Ann Arbor.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lycera Corp has raised $86M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $34M on 2009-04-07.
Most recent recorded round closed around 2015-06-12.
Valuation (modeled)modeled
Provath models Lycera Corp at approximately $1.0B (range $63M–$3.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.49× the median modeled value of Series B Pharmaceuticals companies in 2013–2015 (42 peers) — value vs value, same stage and era. Within the normal band (149% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 11.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 7.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 89% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Lipocine Inc., CARDEAS PHARMA Corp, CoLucid Pharmaceuticals, Inc., Emisphere Technologies Inc, Vasculox, Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.